Austrian Construction Giant STRABAG Expands in Romania With Dual Technical Services Acquisition

The Austrian construction group STRABAG, through its subsidiary STRABAG Property and Facility Services, obtained regulatory clearance to acquire two Romanian technical installation firms, Brenneka Install and Samivo Instal, which together generated about €25.5 million in revenue in 2025 and employ over 230 staff.

Lyft brings ride-hailing service to Europe with unified app experience

Lyft, the US ride‑hailing company, announced the European rollout of its existing app, enabling travelers from North America to book rides in Europe without downloading a new app. The expansion begins with Barcelona and Hamburg and will cover several major European cities by the end of October 2024, with plans to support local currency payments.

Swedish Spatial Transcriptomics Startup Cubase Bio Secures €1 Million Eurostars Grant for Cardiac Drug Discovery Platform

Swedish spatial‑biology startup Cubase Bio teamed up with Austrian organoid company HeartBeat.bio, receiving about €1 million in Eurostars funding to create the FACTS‑3D project, which combines Cubase Bio’s 3D spatial transcriptomics with HeartBeat.bio’s cardiac organoids for high‑throughput drug discovery targeting myocardial fibrosis.

ENPULSION Acquires UK Propulsion Specialist Lift Me Off Following €22.5 Million Growth Round

Vienna‑based ENPULSION, an industrial manufacturer of electric spacecraft propulsion, raised €22.5 million in growth funding and is now acquiring British chemical‑propulsion specialist Lift Me Off to create a full‑stack spacecraft mobility backbone.

Austrian Startup Efferon Expands Blood-Purification Technology After Securing Paediatric Approval in Europe

Austrian startup Efferon, founded in 2016, creates blood‑purification cartridges that remove bacterial toxins and inflammatory mediators to treat sepsis. After receiving European CE MDR approval for its adult device in 2024 and paediatric certification in 2026, the devices have been used in over 25,000 treatments in 44 countries, generating more than €1 million in revenue. Efferon is now pursuing US regulatory pathways, expanding into China, and developing an outpatient solution for post‑sepsis and chronic inflammation.